{
    "relation": [
        [
            "",
            "Axitinib + Gemcitabine",
            "Gemcitabine"
        ],
        [
            "Description",
            "Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks. Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.",
            "Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks."
        ]
    ],
    "pageTitle": "AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00219557?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 425,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987171.38/warc/CC-MAIN-20150728002307-00187-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 859733863,
    "recordOffset": 859697427,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Gemcitabine Drug: AG-013736 Interventions: Pancreatic Neoplasms Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: February 25, 2012 \u00a0",
    "textAfterTable": "Gemcitabine Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks. Participant Flow for 2 periods Period 1: \u00a0 Phase 1 \u00a0 \u00a0 Axitinib + Gemcitabine (Phase 1 Lead-In) \u00a0 \u00a0 Axitinib + Gemcitabine \u00a0 \u00a0 Gemcitabine \u00a0 STARTED \u00a0 \u00a0 8 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 1 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 NOT COMPLETED \u00a0 \u00a0 7 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 Lack of Efficacy \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}